An observational study in Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy and Familial Hypertrophic Cardiomyopathy, sponsored by Montreal Heart Institute. Recruiting at 17 sites in Canada. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Montreal Heart Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada — 5 open to participants now, 11 under way, 4 of them phase 3. Cardiomyopathy, Hypertrophic · Canada.
Among the 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2021, is one of 13 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 16th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →5 of the 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Canada, United States, Brazil and 6 more countries
Ages 6+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Healthy volunteers
Cytokinetics · Sites in Canada, United States, Argentina and 16 more countries
Ages 18–85
University of British Columbia · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 120 across the 13 interventional studies, 544 across the 13 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 26 have an industry lead sponsor. The 10 most frequent:
Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.
Montreal Heart Institute has 1 study filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies in Cardiomyopathy, Hypertrophic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04464655McGill University Health Centre/Research Institute of the McGill University Health CentreA 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease | 2026-12-19 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Cardiomyopathy, Hypertrophic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic Cardiomyopathy registry, biobank and imaging data repository (HiRO-HCM) is a multicenter study that will prospectively enroll patients with HCM as well as those carrying sarcomeric gene variants predisposing to HCM.
The objectives of HiRO-HCM are:
PATIENT ENROLLMENT:
Eligible patients will be included from HiRO sites or collaborating centres. Patients will be contacted by the local investigator or a research coordinator. Willing individuals will be interviewed by the research coordinator and given information about HiRO-HCM. The consent form will be reviewed and discussed with the coordinator. The investigators will also be available for any questions that the coordinator is unable to answer. Potential participants will have sufficient time to consider participating in HiRO-HCM. Written informed consent will be obtained from eligible patients or legal guardians. Participants will be able to withdraw their participation at any time.
BASELINE DATA COLLECTION:
Clinical data will be collected from willing/consented registry participants. All demographic and medical information pertaining to the cardiac history and comorbidities of eligible patients will be collected at baseline, including clinical information, diagnostic test results, genetic testing results, family history and ethnicity, as well as current and previous treatments. Healthcare information will be coded in compliance with Canada's Tri-Council Policy Statement criteria: direct identifiers will be removed and replaced with a unique study code that does not use personal information such as the participant's health number, social insurance number or name. The coded data will be transferred into the clinical research database using a web-based electronic case report form (eCRF), using REDcap. The clinical research database will be managed by the Montreal Health Innovations Coordinating Center (MHICC; mhicc.org). Study participants will be identified by subject number only (research HiRO-HCM ID). The research ID uniquely identifying each subject eCRF within the database will be attributed in REDcap but the master list of registry participants with their study identifiers will be kept separately from the clinical research database. This master list will be stored in an encrypted file within the research office of each site investigators under their supervision. Only the site investigators and their local research staff will have access to this list.
BIOSPECIMEN COLLECTION:
Consented participants will undergo biosampling at enrollment for the primary purpose of DNA isolation and genetic studies. The preferred biosampling method is blood sampling using a standard venipuncture. Blood sampling allows for high quality DNA extraction as well as collection of plasma for future circulating biomarkers studies. As an alternative to blood sampling, collection of saliva using DNA genotek kits, or equivalent, is allowed in the following contexts:
Participants for which saliva collection is chosen should be made aware of the possibility to request a blood sample in the future.
The HiRO-HCM biobank will be directed by the Beaulieu-Saucier Pharmacogenomics Center (PGx; http://www.pharmacogenomics.ca), operating under Good Laboratory/Clinical Practices (GLP/GCP) standards.
DNA isolation and long-term storage will be done at PGx, while long-term storage of plasma samples will be done at the MHI research center, in dedicated freezers located in a room with restricted access. Samples of subjects that withdraw their participation will be destroyed.
IMAGING DATA TRANSFER:
For all consented participants, de-identified transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging data will be transferred to the Montreal Heart Institute imaging core-lab for central interpretation and long term storage. At minimum, the following imaging studies are requested:
For patients that underwent alcohol septal ablation, surgical myectomy and/or cardiac transplantation, the last available TTE and CMR studies prior to all these interventions should also be transferred.
Digital Imaging and Communications in Medicine (DICOM) imaging data will be de-identified prior to transfer. De-identification will be performed at each site, by removing the patient's name and replacing the clinical identification number with the research HiRO-HCM ID. DICOM data will be stored using the Canadian Imaging network infrastructure (canadianimagingnetwork.org).
PATIENT FOLLOW-UP:
Participants with a clinical diagnosis of HCM are expected to undergo yearly clinic visits, as per standard care. Participants without yearly clinic visits will be contacted by phone. Follow-up visits will assess for living status, functional class, as well as for arrhythmic, heart failure and thromboembolic events. Follow-up data will be entered by the local investigator and/or research coordinator into an eCRF managed by the MHICC. De-identified documentation of clinical events including ECG, intracardiac tracing, clinical notes, imaging reports, and procedural reports will be uploaded to the database for centralized ad-hoc event adjudication.
De-identified DICOM images of TTE and CMR studies performed clinically during follow-up will be uploaded to the MHI imaging core-lab similarly as for baseline imaging studies.
For participants that will undergo septal myectomy for drug-refractory obstructive HCM, or cardiac transplantation, surgical tissue samples will be collected using the Qiagen PAXgene tissue preservation system or equivalent, allowing for future somatic DNA, RNA and proteomic analyses. The samples will be stored at the MHI research center.
The HiRO-HCM registry, biobank and imaging data repository is a multicenter collaboration that will prospectively enroll patients with HCM as well as those carrying genetic variants predisposing to HCM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with (1) AND/OR (2)
Clinical diagnosis of HCM, defined as
AND/OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Create a Canadian Research Database, a biobank and an imaging data repository for those affected by hypertrophic cardiomyopathy (HCM) or carrying a sarcomeric gene variant associated with HCM
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2021 (actual). Primary completion is estimated for Dec 2030, 118 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 118 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Feb 2026 → Dec 2030 and completion Aug 2027 → Dec 2035.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →